相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome
Liying Li et al.
CANCERS (2023)
Cancer statistics, 2023
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2023)
Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence
Maryam Abbaspour et al.
EXPERT REVIEW OF VACCINES (2022)
Treatment landscape of triple-negative breast cancer - expanded options, evolving needs
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Bystander CD4+ T cells infiltrate human tumors and are phenotypically distinct
Shamin Li et al.
ONCOIMMUNOLOGY (2022)
Comparison of four methods of colon cancer cell lysates preparation for ex vivo maturation of dendritic cells
Mohammad Roufarshbaf et al.
RESEARCH IN PHARMACEUTICAL SCIENCES (2022)
Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions
Joachim Stoltenborg Granhoj et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2022)
Tumor cell-based vaccine: an effective strategy for eradication of cancer cells
Seyed Amir Sadeghi Najafabadi et al.
IMMUNOTHERAPY (2022)
Glioblastoma, an opportunity T cell trafficking could bring for the treatment
Mehdi Karimi-Shahri et al.
MOLECULAR BIOLOGY REPORTS (2022)
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
Daniel R. Principe et al.
PHARMACOLOGY & THERAPEUTICS (2022)
Efficacy and Safety of Ginger on the Side Effects of Chemotherapy in Breast Cancer Patients: Systematic Review and Meta-Analysis
Soo-Dam Kim et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer
Xi Cao et al.
FRONTIERS IN ONCOLOGY (2021)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
Leisha A. Emens et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Recent Progress on Immunotherapy for Breast Cancer: Tumor Microenvironment, Nanotechnology and More
Yang Li et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2021)
Breast cancer vaccines: Heeding the lessons of the past to guide a path forward
Cinzia Solinas et al.
CANCER TREATMENT REVIEWS (2020)
Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types
X. Zhao et al.
ANNALS OF ONCOLOGY (2020)
The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients
Pierre Rosenbaum et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Comparison of DND and mRNA vaccines against cancer
Zohreh Jahanafrooz et al.
DRUG DISCOVERY TODAY (2020)
Structural insight into T cell coinhibition by PD-1H (VISTA)
Benjamin T. Slater et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
Tommy A. Brown et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial
Cesare Gridelli et al.
BRITISH JOURNAL OF CANCER (2020)
New insight into the role of substance P/neurokinin-1 receptor system in breast cancer progression and its crosstalk with microRNAs
Safieh Ebrahimi et al.
CLINICAL GENETICS (2020)
Breast cancer is a systemic disease optimally treated by a multidisciplinary team
Nadia Harbeck
NATURE REVIEWS DISEASE PRIMERS (2020)
T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast cancer
M. Schmidt et al.
ANNALS OF ONCOLOGY (2020)
Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors
Adviti Naik et al.
FRONTIERS IN ONCOLOGY (2020)
The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer
Xiaoxue Xie et al.
FRONTIERS IN IMMUNOLOGY (2020)
TIM3 comes of age as an inhibitory receptor
Yochai Wolf et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Telomerase-Targeted Cancer Immunotherapy
Eishiro Mizukoshi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Cancer DNA vaccines: current preclinical and clinical developments and future perspectives
Alessandra Lopes et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer
Takeo Shibata et al.
CANCER TREATMENT REVIEWS (2019)
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
Lawrence P. Andrews et al.
NATURE IMMUNOLOGY (2019)
Immunotherapy: A Challenge of Breast Cancer Treatment
Marilina Garcia-Aranda et al.
CANCERS (2019)
Immunotherapy in triple-negative breast cancer
Heather Katz et al.
MEDICAL ONCOLOGY (2018)
Dendritic Cell-Based Cancer Vaccines
Patricia M. Santos et al.
JOURNAL OF IMMUNOLOGY (2018)
DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer
Varun Sasidharan Nair et al.
CLINICAL EPIGENETICS (2018)
High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer
Lijuan Wei et al.
FRONTIERS IN IMMUNOLOGY (2018)
Cemiplimab: First Global Approval
Anthony Markham et al.
DRUGS (2018)
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
Lieve Brochez et al.
EUROPEAN JOURNAL OF CANCER (2017)
Immunotherapy for the treatment of breast cancer
Mariela A. Moreno Ayala et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Tim-3 and its role in regulating anti-tumor immunity
Madhumita Das et al.
IMMUNOLOGICAL REVIEWS (2017)
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Jianjun Gao et al.
NATURE MEDICINE (2017)
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Hyun Tae Lee et al.
SCIENTIFIC REPORTS (2017)
Autoantibody Production in Cancer-The Humoral Immune Response toward Autologous Antigens in Cancer Patients
P. Zaenker et al.
AUTOIMMUNITY REVIEWS (2016)
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
Avery D. Posey et al.
IMMUNITY (2016)
Tim-3 identifies exhausted follicular helper T cells in breast cancer patients
Shiguang Zhu et al.
IMMUNOBIOLOGY (2016)
Tremelimumab-associated tumor regression following after initial progression: two case reports
Akihiko Shimomura et al.
IMMUNOTHERAPY (2016)
Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level
De-Gang Song et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Next-generation TCR sequencing-a tool to understand T-cell infiltration in human cancers
Isabel Poschke et al.
JOURNAL OF PATHOLOGY (2016)
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Woo Young Sun et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Vassiliki A. Boussiotis
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies
Mohammad A. Jafri et al.
GENOME MEDICINE (2016)
Pembrolizumab (Keytruda)
Gerry Kwok et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Dendritic cell vaccines: A review of recent developments and their potential pediatric application
Jennifer D. Elster et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Telomere and Telomerase Therapeutics in Cancer
Yucheng Xu et al.
GENES (2016)
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
Sasha E. Stanton et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8+ and CD4+ T Cells
Wenjie Yin et al.
EBIOMEDICINE (2016)
A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.
Jeffrey R. Infante et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC).
Scott Joseph Antonia et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
Anne Bertrand et al.
BMC MEDICINE (2015)
Long term side effects of adjuvant chemotherapy in patients with early breast cancer
Jessica J. Tao et al.
BREAST (2015)
A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma
Deepa K. Krishnadas et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis
Haiming Yu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Improved biological activity of a single chain antibody fragment against human epidermal growth factor receptor 2 (HER2) expressed in the periplasm of Escherichia coli
Vajihe Akbari et al.
PROTEIN EXPRESSION AND PURIFICATION (2015)
Immunotherapy for the Treatment of Breast Cancer
Brenda Ernst et al.
CURRENT ONCOLOGY REPORTS (2015)
Prognostic and predictive value of PDL1 expression in breast cancer
Renaud Sabatier et al.
ONCOTARGET (2015)
OX40 agonists anc combination immunotherapy: putting the pedal to the metal
Stefanie N. Linch et al.
FRONTIERS IN ONCOLOGY (2015)
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Yu-Hwa Huang et al.
NATURE (2015)
Severe Adverse Immunologic Reaction in a Patient with Glioblastoma Receiving Autologous Dendritic Cell Vaccines Combined with GM-CSF and Dose-Intensified Temozolomide
Duane A. Mitchell et al.
CANCER IMMUNOLOGY RESEARCH (2015)
A phase 1b/2, open-label study to evaluate the safety and tolerability of MEDI6469 in combination with immune therapeutic agents or therapeutic mAbs in patients with selected advanced solid tumors or aggressive B-cell lymphomas.
John D. Powderly et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Effect of alphavirus vaccine encoding HER2 during concurrent anti-HER2 therapies on induction of oligoclonal T cell and antibody responses against HER2.
William Rayford Gwin et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Folate Receptor α Associated With Triple-Negative Breast Cancer and Poor Prognosis
Zhang Zhang et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
Identification and translational validation of novel mammaglobin-A CD8 T cell epitopes
S. D. Soysal et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients with Stable Metastatic Breast Cancer
Venkataswarup Tiriveedhi et al.
CLINICAL CANCER RESEARCH (2014)
Adoptive cellular immunotherapy for the treatment of patients with breast cancer: A meta-analysis
Zheng-Xu Wang et al.
CYTOTHERAPY (2014)
Exploiting the curative potential of adoptive T-cell therapy for cancer
Christian S. Hinrichs et al.
IMMUNOLOGICAL REVIEWS (2014)
The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response
Erika J. Schneble et al.
IMMUNOTHERAPY (2014)
Primary analysis of the prospective, randomized, phase trial of GP2H-GM-CSF Vacilne versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients
Erika J. Schneble et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Aryl hydrocarbon receptor ligands in cancer: friend and foe
Iain A. Murray et al.
NATURE REVIEWS CANCER (2014)
Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells
Venkataswarup Tiriveedhi et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
S. Muenst et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Combinations of TLR Ligands: A Promising Approach in Cancer Immunotherapy
Saskia Stier et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2013)
Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell-Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects
Marieke F. Fransen et al.
CLINICAL CANCER RESEARCH (2013)
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy
Amy E. Moran et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Andrew M. Intlekofer et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
Scott Wilkie et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
Shigeki Chiba et al.
NATURE IMMUNOLOGY (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Future treatment strategies for metastatic breast cancer: curable or incurable?
Hiroji Iwata
BREAST CANCER (2012)
Harnessing DNA-induced immune responses for improving cancer vaccines
Andres A. Herrada et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
Trastuzumab: updatedmechanisms of action and resistance in breast cancer
Thuy Vu et al.
FRONTIERS IN ONCOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Evan J. Lipson et al.
CLINICAL CANCER RESEARCH (2011)
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Steven A. Rosenberg et al.
CLINICAL CANCER RESEARCH (2011)
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Li Wang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma
Tim F. Greten et al.
BMC CANCER (2010)
Anti-HER2 vaccines: new prospects for breast cancer therapy
Maha Zohra Ladjemi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Circulating Soluble CTLA4 (sCTLA4) Is Elevated in Patients With Breast Cancer
Nasrollah Erfani et al.
CANCER INVESTIGATION (2010)
New Insights of CTLA-4 into Its Biological Function in Breast Cancer
H. Mao et al.
CURRENT CANCER DRUG TARGETS (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Telomerase-Based Therapies Emerging Slowly
Vicki Brower
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
Chrystelle Brignone et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide
Jeremy D. Gates et al.
VACCINE (2010)
Overcoming Cancer Immune Tolerance and Escape
Guy T. Clifton et al.
CLINICAL CANCER RESEARCH (2009)
Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER-2/neu peptide (AE37) vaccine
Jarrod P. Holmes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
Silvia Piconese et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
PANVAC™-VF:: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma
Ravi A. Madan et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation
Ana Izcue et al.
IMMUNOLOGICAL REVIEWS (2006)
A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: Preclinical evaluation of IMP321
Sylvie Fougeray et al.
VACCINE (2006)
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould et al.
BRITISH JOURNAL OF CANCER (2006)
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction
E Contardi et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
The TIM gene family regulates autoimmune and allergic diseases
JH Meyers et al.
TRENDS IN MOLECULAR MEDICINE (2005)
Induction of a p95/Nbs1-mediated S phase checkpoint by telomere 3′ overhang specific DNA
MS Eller et al.
FASEB JOURNAL (2003)
A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells:: implications for immunotherapy
AW Lee et al.
VACCINE (2002)
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L Monney et al.
NATURE (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
